Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bingzhi Shangtong is a botanical-based topical aerosol developed by Guizhou Antai Pharmaceutical Co., Ltd. for the treatment of acute closed soft tissue injuries, such as joint sprains. As a Traditional Chinese Medicine (TCM) formulation, it is designed to provide localized analgesic and anti-inflammatory effects when applied to the site of injury. The drug has undergone clinical evaluation in China, including a Phase 1/2 trial (CTR20150132) to assess its safety, pharmacokinetics, and therapeutic efficacy in both healthy volunteers and patients suffering from musculoskeletal trauma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bingzhi Shangtong.